Mankind Pharma
Financials
Estimates*
INR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 62.1b | 77.8b | 87.5b | 103.3b | 115.8b | 131.4b | 147.5b |
% growth | 6 % | 25 % | 12 % | 18 % | 12 % | 13 % | 12 % |
EBITDA | 17.8b | 20.9b | 20.2b | 27.1b | 29.2b | 34.2b | 39.8b |
% EBITDA margin | 29 % | 27 % | 23 % | 26 % | 25 % | 26 % | 27 % |
Profit | 12.9b | 14.5b | 12.8b | 19.1b | 21.9b | 26.0b | 30.9b |
% profit margin | 21 % | 19 % | 15 % | 19 % | 19 % | 20 % | 21 % |
EV / revenue | - | - | - | 8.6x | 8.2x | 7.1x | 6.1x |
EV / EBITDA | - | - | - | 32.8x | 32.6x | 27.3x | 22.7x |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$24.0m | Growth Equity VC | ||
| $215m Valuation: $2.0b | Secondary | |
* | N/A | $529m | IPO |
Total Funding | €21.8m |
Related Content
Recent News about Mankind Pharma
EditMankind Pharma, incorporated in 1995, is one of the largest pharmaceutical companies in India by domestic sales. The company operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors. Mankind Pharma develops, manufactures, and markets a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company's core values are quality, affordability, and accessibility, aiming to provide cost-effective, innovation-based superior quality pharmaceutical products globally to improve patients' lives. Mankind Pharma serves a wide range of clients, including healthcare providers, pharmacies, and consumers. The company generates revenue through the sale of its pharmaceutical and consumer healthcare products. Mankind Pharma is committed to responsible business practices, including stringent policies for environment, health, and safety. The company has an established track record of building and scaling brands in-house and has been recognized for its contributions to the pharmaceutical industry.
Keywords: pharmaceutical formulations, consumer healthcare, acute therapeutic areas, chronic therapeutic areas, quality products, affordability, accessibility, innovation, healthcare providers, pharmacies.